Tracks pregnancy and infant outcomes after ubrogepant or atogepant use
Follows pregnant women with migraine who take ubrogepant or atogepant.
Key facts
- Who runs it
- AbbVie
- Where
- Durham, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Registry title
- Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
- Status
- Recruiting
- People taking part
- 1,884 people, planned
- Started
- 10 Jan 2023
- Expected to end
- Jan 2036
- Type of study
- Observational, 3 groups
- Record updated
- 15 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with migraine in the United States or Canada. Some took Ubrelvy or Qulipta during pregnancy, others did not.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Migraine diagnosed by the patient's health care provider
- Earlier treatment
- Three groups: took at least 1 dose of Ubrelvy during pregnancy; took at least 1 dose of Qulipta during pregnancy; or never took Ubrelvy or Qulipta, or stopped Ubrelvy 2 days or Qulipta 5 days before conception.
Main reasons for not taking part
- Took any other gepant or CGRP monoclonal antibody before conception or during pregnancy before enrollment
- No longer pregnant when enrolling (the pregnancy has already ended and the outcome is known)
This trial only enrols pregnant participants. The registry sentence this rests on: Qualify as a prospective enrollment, defined as currently pregnant.
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Within the United States or Canada
- Qualify as a prospective enrollment, defined as currently pregnant
- A diagnosis of migraine by the patient's health care provider (HCP)
- Provide contact information for the participant and her and her infant(s)', if applicable, HCPs
- Authorize their HCP(s) to release maternal and infant medical information to the registry, upon request
- Provide sufficient information to confirm eligibility for 1 of following:; Ubrelvy-exposed women with migraine: documented information indicating that at least 1 dose of Ubrelvy was taken during pregnancy, including the estimated number of administrations per trimester; Qulipta-exposed women with migraine: documented information to indicating that at least 1 dose of Qulipta was taken during pregnancy, including start and stop date(s) of administration; Internal comparator: Ubrelvy/Qulipta-unexposed pregnant women with migraine: documented information indicating that they have, a) never taken Ubrelvy and/or Qulipta, or b) discontinued Ubrelvy 2 days prior or Qulipta 5 days prior to conception
Who cannot take part
- Documentation of exposure to any gepants (acute or preventive) other than Ubrelvy and Qulipta, or CGRP monoclonal antibodies, from 5 halflives of the respective treatment prior to conception or at any point during pregnancy before enrollment
- Women who are no longer pregnant (retrospective cases women for whom the pregnancy has already ended, and the outcome of pregnancy is known at the time of enrollment)
- For further clarification of inclusion/exclusion please contact the investigator to the end of this section in case anything is unclear to a potential patient, etc
Where in United States
Also in 1 other country, 1 site
- IqviaDurham, United StatesTaking people
About the trial
What the trial wants to find out
Migraine is a common neurological disorder typically characterized by attacks of throbbing or pulsating headache on one side of the head of moderate to severe pain intensity. The purpose of this study is to evaluate fetal, maternal, and infant outcomes through 12 months of age among women exposed to Ubrelvy or Qulipta during pregnancy, as well as in 2 comparator groups.
Read full original descriptionShow less
Ubrelvy (ubrogepant) and Qulipta (atogepant) are approved drugs for the acute treatment of migraine in adults. Approximately 628 pregnant women with migraine exposed to Ubrelvy, 628 pregnant women with migraine exposed to Qulipta and 628 pregnant women with migraine in comparator group will be enrolled in this study in the United States.
Participants enrolled in the Ubrelvy-exposed group and Qulipta-exposed group will receive Ubrelvy and Qulipta respectively as prescribed by their physician.
The 3 groups in the trial
- Ubrelvy-Exposed Women With Migraine
Pregnant women with migraine who took at least 1 dose of Ubrelvy, the exposure of interest, at any time during pregnancy as part of routine care.
- Qulipta-Exposed Women With Migraine
Pregnant women with migraine who took at least 1 dose of Qulipta, the exposure of interest, at any time during pregnancy as part of routine care.
- Ubrelvy/Qulipta-Unexposed Women With Migraine
Pregnant women with migraine who have never taken Ubrelvy and/or Qulipta, OR discontinued Ubrelvy 2 days prior or Qulipta 5 days prior to conception.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Ubrelvy and Qulipta Pregnancy Exposure Registry EMPRESS: An Observational, Prospective Study to Assess the Safety of Ubrelvy (Ubrogepant) and Qulipta (Atogepant) During Pregnancy
- Plain-language title
- Tracks pregnancy and infant outcomes after ubrogepant or atogepant useGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 December 2025